Figure 2. A) Effect of JV-GL1 and butaprost on IOP of SI-OHT mice relative to the pre-treatment time point (δIOP). Single, bilateral topical applications of 0.01% JV-GL1 to SI-OHT C57BL/6J mice (first red arrow) reduced IOP by -2.3 [-3.4, -1.2] mmHg (P =0.01; n=9) after 3 hours and maintained significant suppression for up to 6 days (-2.8 [-3.7, -2.0]; P =0.001; n=9). Comparatively, 0.01% butaprost reduced IOP after 3 hours by -2.5 [-4.2, -1.0] mmHg, returning to pre-treatment levels by the following 2-day time point (-0.8 [-1.5, 0.0] mmHg; P =0.6; n=9). A second unilateral topical application of 0.01% JV-GL1 (second red arrow) significantly reduced IOP of the treated eye by -2.3 [-3.4, -1.2] mmHg after 3 days, compared to contralateral vehicle treated eye (P =0.04, n=9). Error bars are 95% confidence intervals.B) 3 days after treatment with JV-GL1, outflow facility was not significantly altered (18% [-7%, 50%]; P=0.2, n=9 pairs) relative to vehicle treated eyes of SI-OHT C57BL/6J mice. Each data point shows the relative difference in reference facility,\(\text{\ C}_{r}\), between paired eyes comparing the treated with respect to the untreated control eye. The error bars represent the 95% confidence intervals on the relative difference in \(\text{\ C}_{r}\). The light shaded region represents the best estimate of the sample distribution, with the geometric mean and two-sigma limits represented by the thick and thin horizontal white lines respectively. Dark central bands within the distribution represent the 95% CI on the estimated mean.